Amphastar adds Anthony Pierce to board, expanding it to 11 directors
Amphastar Pharmaceuticals increased its board from 10 to 11 seats on July 9, 2026, and appointed Anthony Pierce as a Class III director, effective immediately. The board deemed him independent under Nasdaq listing standards, and he has no committee assignments at this time.
Key points
- Board size increased from 10 to 11 directors; Pierce appointed effective immediately
- Pierce's term runs until the 2028 annual meeting of stockholders
- Annual cash retainer of $55,000, pro-rated for his start date
- Initial equity grant with aggregate grant date fair value of $300,000, split 50% restricted stock units and 50% stock options, vesting on the first anniversary
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 13, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.